OmniScience, a pioneering data intelligence company in clinical trials, is excited to announce the appointment of Kris Kuhner as Senior Vice President of Business Development. With a career spanning over two decades and encompassing leadership roles at top organizations such as PPD, WCG, and Medable, Kris brings an exceptional understanding of clinical trial operations and customer-centric solutions to OmniScience. This also signals OmniScience's commitment to strategic growth and its dedication to enhancing genAI innovations in clinical development.
In his new role, Kris will spearhead business development initiatives to deepen OmniScience’s relationships with pharmaceutical sponsors and Contract Research Organizations (CROs), with a focus on supporting clinical trial leaders in navigating complex data landscapes. His appointment comes as OmniScience continues to establish itself as a transformative player in the clinical trial industry, aiming to unify disparate clinical trial data and enhance insights through AI.
"We are thrilled to welcome Kris to the OmniScience team,” beamed Angela Holmes, CEO of OmniScience. “His deep expertise in clinical trial operations and strategic insights align perfectly with our mission to drive innovation and efficiency through genAI-unified solutions. Kris’s leadership will be instrumental as we continue to expand our impact and bring real-time data insights to clinical trials."
As a seasoned business development executive, Kris has a proven track record of building and managing strategic partnerships in clinical trials. Throughout his career, he has worked closely with industry leaders focusing on driving innovation and operational excellence. In joining OmniScience, Kris is excited to leverage his extensive experience to contribute to OmniScience’s mission of transforming clinical trial data into actionable insights.
Q: What attracted you to OmniScience?
A: "After years of working with organizations to support their clinical trial innovations, I was drawn to OmniScience’s unique vision of creating an interoperable, data agnostic AI solution for real-time, actionable insights. Time is literally money when it comes to clinical operations, so every hour we can save, or manual steps we can eliminate, matter.
Q: What has been the biggest challenge or opportunity in your new role?
A: "OmniScience has created a new category. My biggest challenge when speaking to potential partners is that Vivo doesn't fit into an existing box. Being first to market is exciting, but it also means we need to help others understand the unique value Vivo brings as a trailblazer in AI clinical trial operations insights."
Q: What are you most excited about as the commercial pipeline expands?
A:"I have built an extensive network of clients and amazing relationships over the years. I am most excited about being able to finally help teams truly innovate and be more efficient and effective. I hope we can free people up to truly do what they were hired to do and reduce much of the daily noise!"
